High-dose (5000-μg) intravitreal ganciclovir combined with highly active antiretroviral therapy for cytomegalovirus retinitis in HIV-infected patients in Venezuela

European Journal of Ophthalmology

Volumn 15, Issue 5, 2005, Pages 610-618

  Arevalo, J Fernando ^a   Garcia, R A ^a   Mendoza, A J ^a  

^a Clinica Oftalmologica Centro Caracas   (Venezuela)

Author keywords

Cytomegalovirus retinitis; High dose intravitreal ganciclovir; Highly active antiretroviral therapy; HIV infected patients

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; GANCICLOVIR; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG MEGADOSE; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECOVERY UVEITIS; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; RETINA DETACHMENT; RETINITIS; SYSTEMIC THERAPY; TREATMENT OUTCOME; UVEITIS; VIRUS REACTIVATION; VISUAL ACUITY;

EID: 26444461508     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210501500512     Document Type: Article

References (35)

1. Holland GN, Repose JS, Pettit TH, et al. Acquired immune deficiency syndrome: ocular manifestations. Ophthalmology 1983; 90: 859-73.
2. Kupperman BD, Petty JG, Richman DD, et al. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 1993; 115: 575-82.
3. Lowder CY, Butler CP, Dodds EM, et al. CD8+ lymphocytes and cytomegalovirus in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1995; 120: 283-90.
4. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-6.
5. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998; 178: 70-9.
6. Skiest DJ. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy (HAART). Am J Med Sci 1999; 317: 318-35.
7. Tural C, Romeu J, Sirera G, et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis 1998; 177: 1080-3.
8. Macdonald JC, Torriani FJ, Morse LS, et al. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998; 177: 1182-7.
9. Whitcup SM, Fortin E, Lindblad AS, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA. 1999; 282: 1633-7.
10. Cantrill HL, Henry K, Melroe NH, et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir. Long-term results. Ophthalmology 1989; 96: 367-74.
11. Heinemann MH. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch Ophthalmol 1989; 107: 1767-72.
12. Cochereau-Massin I, Lehoang P, Lautier-Frau M, et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1991; 98: 1348-53.
13. Young SH, Morlet N, Heery S, et al. High dose intravitreal ganciclovir in the treatment of cytomegalovirus retinitis. Med J Aust 1992; 157: 370-3.
14. Young S, Morlet N, Besen G, et al. High-dose (2000-microgram) intravitreous ganciclovir in the treatment of cytomegalovirus retinitis. Ophthalmology 1998; 105: 1404-10.
15. Pavan PR, DeGregorio PG, Menosky MM, et al. Safety of 4000 microgram doses of intravitreal ganciclovir. The Vitreous Society Online Journal 1996; 1: 1-7.
16. Morlet N, Young S, Naidoo D, et al. High dose intravitreal ganciclovir for CMV retinitis: a shelf life and cost comparison study. Br J Ophthalmol 1995; 79: 753-5.
17. Freeman WR, Lerner CW, Mines JA, et al. A prospective study of the ophthalmic findings in the acquired immune deficiency syndrome. Am J Ophthalmol 1984; 97: 133-142.
18. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989; 107: 75-80.
19. Holland GN, Buhles WC, Mastre B, et al. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy: use of a standardized system for the assessment of disease outcome. Arch Ophthalmol 1989; 107: 1759.
20. Isenberg SJ, Apt L, Yoshimori R, et al. Chemical preparation of the eye in ophthalmic surgery. IV. Comparison of povidone-iodine on the conjunctiva with a prophylactic antibiotic. Arch Ophthalmol 1985; 103: 1340-2.
21. Apt L, Isenberg SJ, Yoshimori R, et al. Outpatient topical use of povidone-iodine in preparing the eye for surgery. Ophthalmology 1989; 96: 289-92.
22. Karavellas MP, Plummer DJ, Macdonald JC, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 1999; 179: 697-700.
23. Kuppermann BD, Holland GN. Immune recovery uveitis. Am J Ophthalmol 2000; 130: 103-6.
24. Karavellas MP, Song M, Macdonald JC, et al. Long-term posterior and anterior segment complications of immune recovery uveitis associated with cytomegalovirus retinitis. Am J Ophthalmol 2000; 130: 57-64.
25. Arevalo JF, Mendoza AJ, Ferretti Y. Immune recovery uveitis in AIDS patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy in Venezuela. Retina 2003; 23: 495-502.
26. Arevalo JF. Ocular manifestations associated to the human immunodeficiency virus: a prospective study in ambulatory patients. Rev Oftalmol Venez 1992; 48: 20-6.
27. Carrasco E. Access to treatment as a right to life and health. Can HIV AIDS Policy Law Rev 2000; 5: 102-3.
28. Studies of the Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326: 213-20.
29. Henderly DE, Freeman WR, Causey DM, et al. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology 1987; 94: 425-34.
30. LeHoang P, Girard B, Robinet M, et al. Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1989; 96: 865-73.
31. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991; 163: 716-9.
32. Arevalo JF, Gonzalez C, Capparelli EV, et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995; 172: 951-6.
33. Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999; 340: 1063-70.
34. Lalezari J, Lindley J, Walmsley S, et al. A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis. J Acquir Immune Defic Syndr 2002; 30: 392-400.
35. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346: 1119-26.